This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

POZEN’S PA32540 Associated With A Significantly Lower Rate Of Endoscopic Gastroduodenal Ulcers As Compared To Aspirin Alone In Patients With Diabetes

POZEN Inc. (NASDAQ: POZN), a pharmaceutical company committed to transforming medicine that transforms lives, presented a post-hoc analysis of diabetic subpopulation results from two Phase 3 PA32540 (325 mg enteric-coated (EC) aspirin / 40 mg immediate-release omeprazole) studies at the American Diabetes Association’s 73 rd Scientific Session. Nearly 40% of patients in the Phase 3 studies had diabetes and were on aspirin (325 mg) for secondary prevention of cardiovascular (CV) events. In this subpopulation of four hundred patients, PA32540 was associated with a significantly lower rate of endoscopic gastroduodenal ulcers, as compared to taking aspirin alone (2.3% vs. 11.2%, p<0.001). A lower rate of treatment discontinuation was also shown for this PA32540 subpopulation (1.4% vs. 5.9%, p=0.018). These data were presented for the first time on Monday, June 24 th at noon (CT) at the McCormick Place Convention Center in Chicago, Illinois, as poster board number 425-P.

“Patients with diabetes and prior cardiovascular events may require daily life-long treatment with aspirin,” said John G. Fort, M.D., Chief Medical Officer of POZEN and co-author of the poster. “We are pleased that these findings support the use of an integrated tablet of omeprazole and aspirin as antiplatelet therapy for secondary cardiovascular prevention in diabetic patients at risk for gastric ulcers.”

Diabetes is associated with an approximate 2-fold increased risk for cardiovascular disease, including non-fatal myocardial infarction and ischemic stroke. The American Diabetes Association Standards of Medical Care specifically recommend low-dose aspirin therapy for secondary cardiovascular disease prevention in patients with diabetes and a history of cardiovascular disease. Studies have shown that patients (including those with a history of diabetes) who experience upper gastrointestinal complications from aspirin therapy may stop treatment. Discontinuations or interruptions in aspirin therapy in cardiovascular disease patients have been reported to increase the risk of future cardiovascular events.

1 of 5

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,098.45 +18.88 0.11%
S&P 500 2,003.37 +6.63 0.33%
NASDAQ 4,580.2710 +22.5760 0.50%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs